Curis, Inc.

... ...
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -1.41%131.110.0%$2534.51m
BNGOBioNano Genomics, Inc. 12.58%9.310.0%$1903.04m
GILDGilead Sciences, Inc. 0.37%67.231.0%$665.17m
AMGNAmgen, Inc. 1.15%254.931.3%$566.38m
CRSPCRISPR Therapeutics AG 1.46%187.800.6%$493.07m
ALXNAlexion Pharmaceuticals, Inc. 1.19%159.752.0%$482.53m
REGNRegeneron Pharmaceuticals, Inc. 1.35%542.712.7%$480.30m
NVAXNovavax, Inc. 2.35%125.2892.9%$438.91m
ILMNIllumina, Inc. 0.43%406.603.5%$395.97m
SRPTSarepta Therapeutics, Inc. 1.76%98.6313.8%$362.88m
VRTXVertex Pharmaceuticals, Inc. 0.62%240.121.9%$362.65m
BIIBBiogen, Inc. -0.34%269.201.7%$325.55m
BNTXBioNTech SE 1.68%107.200.0%$304.57m
EXASEXACT Sciences Corp. 1.34%150.0519.6%$243.09m
PACBPacific Biosciences of California, Inc. 2.09%37.077.4%$235.63m

Company Profile

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.